Melanotan II
MT-II, MT-2, Melanotan 2, "tan jab", "Barbie drug"; cyclic [Nle4, D-Phe7]-α-MSH(4-10) analog
The Ground Truth Score
four plain questions, never one numberReal tanning effect, real risks, no finished safety trial
Bottom line
Melanotan II reliably and visibly darkens skin in humans, but it was never carried through full clinical development for tanning, it is unapproved and illegal to sell for human use in every major market, and a substantial published case-report literature ties it to melanoma, priapism, rhabdomyolysis, renal infarction, and other serious events.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) gray-market practice typically involves a 10 mg lyophilized vial reconstituted with bacteriostatic water (e.g., 2 mL for 5 mg/mL, so 0.1 mL / 10 IU on an insulin syringe ≈ 0.5 mg).
Reported, not prescribed. Verify your vial and your math.
First documented human use
First documented human use was a 1996 University of Arizona open-label pilot phase-I study (Dorr, Levine, Hruby, Hadley and colleagues) in which healthy male volunteers received subcutaneous MT-II and developed measurable tanning within about five low-dose injections; the trial also incidentally documented penile erection, nausea, and flushing. No adequately powered, blinded, controlled efficacy-and-safety trial of MT-II for tanning has ever been completed or submitted for approval, its erectogenic property was instead spun off into a separate drug (bremelanotide).
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A synthetic, non-selective analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that drives the skin to produce eumelanin, the dark pigment, so users tan with far less UV exposure.
- Activates MC1R (pigment) but also MC3R/MC4R/MC5R, which is why users also commonly report increased libido/spontaneous erections and reduced appetite.
- Effects are objective and visible: skin darkening shows in photographs and is not plausibly placebo.
- Two structurally related melanocortin peptides did complete FDA approval, afamelanotide/Scenesse (MC1R-selective, for erythropoietic protoporphyria) and bremelanotide/Vyleesi (derived from MT-II's erectile effect, for hypoactive sexual desire), but MT-II itself was never one of them.
- Sold widely online as a 'research peptide' or nasal spray despite being unapproved and illegal to market for human use.
The data behind each bullet
What actually backs it
A 1996 University of Arizona pilot phase-I trial in humans showed subcutaneous MT-II produced visible tanning within roughly five low-dose injections, the first and most-cited human evidence the compound works.
Open-label pilot phase-I human study (Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME, 1996); small, uncontrolled, but genuine human data establishing the pigmentary effect.
PubMed: Dorr 1996 phase-I MT-II pilot (PMID 8637402) ↗MT-II is non-selective across melanocortin receptors (MC1R/MC3R/MC4R/MC5R), which is why the same dose that tans also commonly causes erections, nausea, and appetite loss.
Consistent across the foundational human pilot (which incidentally documented erections) and pharmacology reviews; the off-target MC4R effect was deliberate enough that it became the basis for bremelanotide.
PubMed: melanotan II melanocortin receptor pharmacology ↗MT-II use is associated in multiple published case reports with melanoma and with darkening/proliferation of melanocytic nevi (moles).
Several independent human case reports and case-report reviews describe melanoma diagnosed during/after use and mole darkening or new dysplastic nevi; association only, causation not established.
PubMed: melanotan II melanoma nevi case report ↗MT-II has been linked in case reports to severe systemic events: priapism requiring intervention, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome.
Multiple individual human case reports (e.g., a ~39-year-old man with systemic toxicity, rhabdomyolysis and renal dysfunction after a 6 mg internet-sourced dose); rare but serious, documented in peer-reviewed literature.
PubMed: melanotan II rhabdomyolysis renal infarction priapism ↗MT-II is not approved for any indication and is illegal to sell for human use; regulators (FDA, MHRA, TGA, EMA) have issued warnings, and FDA sent a warning letter to a US seller (Melanocorp).
Regulatory fact, not a clinical-efficacy claim: FDA warning letter and international agency warnings are documented; grade reflects certainty of the regulatory status, not benefit.
FDA: warning letter / unapproved melanotan ↗A separate MC1R-selective melanocortin peptide (afamelanotide / Scenesse) did complete Phase III and gain FDA approval in 2019, but for erythropoietic protoporphyria, not cosmetic tanning, and it is a different molecule from MT-II.
FDA approval of afamelanotide is established fact; included only to prevent the common conflation, it does NOT transfer evidence to MT-II.
FDA/DailyMed: Scenesse (afamelanotide) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism: MT-II is a synthetic, cyclic, more metabolically stable analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is presumed to bind and activate melanocortin receptors non-selectively. MC1R on melanocytes drives eumelanin (dark pigment) synthesis, producing tanning, while activation of MC3R/MC4R/MC5R is the assumed basis for the off-target sexual (erectile/libido), appetite-suppressing, and autonomic/cardiovascular effects. The pigmentary mechanism is well supported by human data; calling it 'assumed' applies mainly to the breadth and dose-dependence of the systemic effects. Not an approved drug.
Dosing & handling
What users and clinicians report
Reported (not prescribed) gray-market practice typically involves a 10 mg lyophilized vial reconstituted with bacteriostatic water (e.g., 2 mL for 5 mg/mL, so 0.1 mL / 10 IU on an insulin syringe ≈ 0.5 mg). Reported loading is roughly 0.25 mg subcutaneously daily or every other day, sometimes titrated up toward 0.5–1 mg as tolerated, until desired pigmentation, then a lower 'maintenance' dose once or twice weekly. Lower starting doses are reported to reduce nausea/flushing.
These numbers are scraped from vendor and forum protocols, not clinical guidelines, and carry no safety endorsement. Severe toxicity case reports involved single internet-sourced doses in the multi-milligram range (e.g., 6 mg), so 'more for a faster tan' is exactly the behavior tied to rhabdomyolysis and renal injury. Gray-market vial labeling can be inaccurate, so the actual delivered dose is uncertain. There is no antidote and no monitoring; this profile reports what people do, and the honest position is that the safe dose is unknown.
Timing & food
Subcutaneous injection; timing is not food-dependent in the way an oral drug would be, but users commonly dose in the evening because the most prominent acute side effects, nausea, flushing, and (in men) spontaneous erections, are easier to sleep through than to function around. Because MT-II potentiates UV-driven pigmentation, some users time modest sun/UV exposure during a course to accelerate tanning, which simultaneously raises the melanoma concern. Lower initial doses are reported specifically to blunt first-dose nausea.
Half-life
Short plasma half-life, commonly reported around 33 minutes to roughly 1 hour, but the biological (melanogenic) effect outlasts it substantially, with pigmentation induced for about 48–72 hours per injection, which is why visible tanning accumulates over days while the peptide itself clears within hours.
Reconstitution sensitivity
Supplied as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water, swirl gently rather than shaking (peptides are shear-sensitive). Store the lyophilized vial frozen (around −20 °C / −4 °F or below) and protected from light; once reconstituted, refrigerate at 2–8 °C and use within roughly 1–2 weeks. Do not re-freeze reconstituted solution, ice-crystal formation degrades the peptide. Gray-market sourcing means cold-chain and purity during shipping are unverifiable, an additional handling risk beyond the user's control.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High volume. MT-II has one of the larger real-world user footprints among gray-market peptides, sold widely online for over 15 years, heavily promoted on social media (including TikTok nasal-spray trends), with abundant forum and before/after reporting plus enough clinical encounters to generate a recurring case-report literature.
Consistency
Highly consistent on the core effects: users near-universally report that it works as a tanning agent and that nausea, flushing, appetite suppression, mole/freckle darkening, and (in men) libido/erection effects are common. The anecdotal record and the published human/clinical record agree closely here, unusual for this category, which is why both the benefit signal and the side-effect signal are rated strong.
Source credibility
Mixed-to-reasonable. Much online content is affiliate/vendor material selling 'research peptides' and is discounted accordingly, but the central claims (it tans, it causes nausea/erections, moles darken) are independently corroborated by peer-reviewed human studies and case reports, so the load-bearing signal does not rest on vendors. Long-term safety reassurance from forums, by contrast, carries low credibility against the documented severe-event reports.
- Users broadly agree it works, reporting a noticeably deeper, faster, longer-lasting tan with far less sun than usual, which is the main reason the compound stays popular despite its illegality (anecdote).
- Nausea and flushing in the first hour after injection, plus reduced appetite (sometimes with unintended weight loss), are described as common and dose-related; many report starting low and dosing at night to manage them (anecdote).
- Men frequently mention spontaneous erections and higher libido as a notable, sometimes inconvenient, side effect, often the second thing they bring up after the tan (anecdote).
- Experienced users and clinicians alike caution that moles, freckles, and scars darken disproportionately and new moles can appear, and advise watching pigmented lesions closely because changes 'get lost in the tan', the recurring real-world worry that overlaps with the melanoma case reports (anecdote).
Placebo risk, Low
Placebo risk is Low because the headline effect, skin darkening, is objective, measurable, and visible in photographs, not a subjective feeling. The libido/erection and appetite effects are likewise physiological and consistent with the known MC4R mechanism. The thing that is NOT reassured by low placebo risk is safety: a real, verifiable effect from a non-selective hormone agonist is exactly what makes the unproven long-term risks worth taking seriously.
Risk panel
What could go wrong
Adverse events
Common and well-attested from human use: nausea and facial flushing (frequently in the first hour post-dose), reduced appetite with unintentional weight loss, spontaneous erections/increased libido in men, and disproportionate darkening of moles, freckles, scars, and nails (melanonychia). Severe but rarer events documented in peer-reviewed case reports include priapism requiring intervention, rhabdomyolysis, acute kidney injury / renal infarction, posterior reversible encephalopathy syndrome, and melanoma diagnosed during or after use.
Theoretical concerns
Because MT-II is a potent, non-selective melanocortin agonist, it acts on receptors governing pigmentation, sexual function, appetite, cardiovascular tone, and immune signaling simultaneously, so unintended systemic effects are mechanistically expected, not surprising. The central concern is melanoma: a drug that stimulates melanocyte activity and is known to darken and change existing nevi raises a biologically plausible (though unproven) malignancy worry, which is exactly the signal you cannot afford to be wrong about and which no trial has powered to rule out.
Contraindications
Anyone with personal or family history of melanoma or atypical/dysplastic nevus syndrome, or numerous/changing moles. Cardiovascular disease or uncontrolled hypertension (melanocortin agonism can raise blood pressure). Pregnancy or breastfeeding. Because effects on appetite, mood, and the cardiovascular and renal systems are real, anyone on relevant medications or with renal impairment should treat it as off-limits. No prescriber oversight exists for gray-market product, which compounds every contraindication.
Honest unknowns
There is no long-term human safety data, no defined safe cumulative dose, and no established melanoma risk quantification. Gray-market product quality is a major unknown: online MT-II varies in purity, actual peptide content, sterility, and contaminants, and nasal-spray formulations add uncertain, uncontrolled dosing. The real-world adverse-event denominator is unknown because most use is unreported, so case reports almost certainly understate frequency.
Confound watch
Tanning attribution is muddied by concurrent UV exposure (sun/beds), self-tanner/bronzer use, and seasonality. MT-II's own effect potentiates with UV, so users rarely isolate it. The libido/erection effect is easily conflated with PT-141 (bremelanotide), which is frequently stacked or sold alongside MT-II. Appetite suppression and weight loss are commonly co-attributed to GLP-1 agonists or stimulants users may be running at the same time.
History
Discovery → first use → status
Heads up: the legal status is moving (2026)
This one got put on the FDA's Category 2 'do not compound' list back in 2023. In April 2026 the FDA moved to pull it back off that list, and there's a July 2026 advisory meeting weighing whether it can be legally compounded again. None of that is final, and none of it makes anything proven or safe. It just means the legal picture is changing fast, so check the date on anything you read about whether this is allowed.
FDA peptide compounding update, 2026 ↗- 1980s–early 1990sMT-II developed at the University of Arizona as a superpotent, cyclic, non-selective alpha-MSH analog ([Nle4, D-Phe7] backbone) intended as a UV-sparing tanning ('sunless tanning') agent.
- 1996First documented human use: open-label pilot phase-I trial shows visible tanning within ~5 low-dose subcutaneous injections; erections, nausea, and flushing noted as effects.
- Late 1990s–2000sMT-II's erectogenic (MC4R) effect is spun off into bremelanotide (PT-141); MT-II itself is never carried through definitive efficacy/safety trials for tanning.
- 2009FDA issues a warning letter to a US distributor (Melanocorp) for illegally selling/marketing MT-II; regulators in the UK, Australia, and EU issue parallel warnings over following years.
- 2010s–2020sGrowing case-report literature ties unregulated MT-II use to melanoma, dysplastic nevi, priapism, rhabdomyolysis, renal infarction, and encephalopathy; gray-market online and nasal-spray sales surge via social media despite illegality.
- 2019The related but distinct MC1R-selective peptide afamelanotide (Scenesse) gains FDA approval for erythropoietic protoporphyria, frequently mis-cited as validation of MT-II, which it is not.
- 2020sInvestigational/academic trials of MT-II as an adjunct to NB-UVB phototherapy for vitiligo repigmentation appear on registries; MT-II remains unapproved for tanning or any indication.
Verification
The COA standard, applied
Cross-checked the foundational human evidence against PubMed (1996 Dorr/Levine/Hruby/Hadley phase-I pilot, PMID 8637402) and confirmed the regulatory status via FDA (Melanocorp warning letter) plus DermNet's clinical overview and the documented FDA/MHRA/TGA/EMA warnings. Severe adverse events (melanoma association, priapism, rhabdomyolysis, renal infarction, PRES, nevi changes) corroborated across multiple independent peer-reviewed case reports rather than a single source. Pharmacokinetics (~33 min plasma half-life vs 48–72 h melanogenesis) and handling cross-checked across multiple sources. Analog context (afamelanotide/Scenesse approved 2019; bremelanotide/Vyleesi) verified to prevent evidence being mis-transferred to MT-II. No PMIDs, statistics, titles, or author names were invented; citations are PubMed search and FDA/DailyMed URLs.
The full verification standard →Sources
Where this comes from
- DermNet NZ. Melanotan II (clinical overview) ↗· Dermatology reference: mechanism, unapproved status, short- and long-term side effects, melanoma/nevi and rhabdomyolysis/encephalopathy concerns; states it is not recommended for anyone to use.
- PubMed. Melanotan II phase-I human pilot (Dorr 1996, PMID 8637402) ↗· First documented human use establishing the tanning effect; small open-label pilot, also noted erections/nausea.
- PubMed. MT-II severe adverse events (rhabdomyolysis / renal infarction / priapism) ↗· Peer-reviewed case reports of systemic toxicity, including a multi-mg internet-sourced dose causing rhabdomyolysis and renal dysfunction.
- PubMed. MT-II melanoma / melanocytic nevi associations ↗· Case reports/reviews of melanoma diagnosed during or after use and mole darkening / new dysplastic nevi; association, not proven causation.
- FDA. Warning Letters (Melanocorp / unapproved melanotan) ↗· FDA warning letter to a US seller; MT-II is unapproved and illegal to market for human use. MHRA, TGA, and EMA have issued parallel warnings.
- DailyMed. Scenesse (afamelanotide) ↗· FDA-approved MC1R-selective melanocortin peptide for erythropoietic protoporphyria, a DIFFERENT molecule from MT-II, included to prevent conflation.
- ClinicalTrials.gov, melanotan / melanocortin tanning & vitiligo studies ↗· Registry of investigational MT-II work (e.g., NB-UVB adjunct for vitiligo); confirms no completed approval-grade tanning trial.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.